EGRX News and Press, Eagle Pharmaceuticals Inc. From 05/09/22

Eagle Pharmaceuticals press release (NASDAQ:EGRX): Q1 Non-GAAP EPS of $3.41 misses by $0.25. Revenue of $115.9M (+181.0% Y/Y) misses by $7.53M. For further details see: Eagle Pharmaceuticals Non-GAAP EPS of $3.41 misses by $0.25, revenue of $115.9M misses by $7.53M

Q1 2022 net income was $3.47 per basic and $3.41 per diluted share and adjusted non-GAAP net income * was $4.10 per basic and $4.04 per diluted share Q1 2022 total revenue was $115.9 million, up from $41.2 million in Q1 2021 Achieved sales of $34.3 million of vasopressin, with...

WOODCLIFF LAKE, N.J., April 28, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2022 first quarter financial results on Monday, May 9, 2022, before the market opens. ...

WOODCLIFF LAKE, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has reached a settlement agreement with Hospira, Inc (“Hospira”). Eagle had asserted two Orange Bo...

Eagle Pharmaceuticals (NASDAQ:EGRX) is acquiring U.K.-based Acacia Pharma Group (OTCPK:ACPGF). The terms of the proposed transaction value Acacia’s existing issued and to be issued share capital at ~€94.7M, or €0.90 per share. Eagle will pay ~€71.6M in cash and the...

Expects to add two U.S. Food and Drug Administration (“FDA”)-approved, new chemical entities (“NCEs”) with patent life into 2031 and expand acute care footprint Commercialized assets, BARHEMSYS ® (amisulpride for injection) and BYFAVO ® ...

Eagle Pharmaceuticals, Inc. (EGRX) Q4 2021 Earnings Conference Call March 07, 2022, 08:30 AM ET Company Participants Lisa Wilson - Investor Relations Scott Tarriff - Founder, Chief Executive Officer, President Brian Cahill - Chief Financial Officer Conference Call Participants Tim Lugo - Will...

Image source: The Motley Fool. Eagle Pharmaceuticals (NASDAQ: EGRX) Q4 2021 Earnings Call Mar 07, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: Eagle Pharmaceuticals (EGRX) Q4 2021 Earnings Call Transcript

Entrance of generic competitor to Vasostrict materially hurting revenue. QWO uptake seems slow with concerns around discoloration side-effect. Q1 guide implies leverage rising dangerous levels. Bankruptcy seems like an increasingly likely option. For further details see:...

Eagle Pharmaceuticals press release (NASDAQ:EGRX): Q4 Non-GAAP EPS of $0.85 misses by $0.09. Revenue of $42.32M (-15.2% Y/Y) misses by $8.76M. “With two important launches in early 2022, Eagle is off to a great start. The initial impressive revenue generated from vasopressin and PEMFEX...